Arcoxia on track
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck is "on track" to re-submit Arcoxia in December, the firm tells analysts Dec. 9. Merck first submitted an NDA for the second-generation COX-2 inhibitor in 2001; the application was withdrawn due to concerns about cardiovascular safety and dosing for acute pain. The expanded NDA will cover osteoarthritis, rheumatoid arthritis, acute pain, dysmenorrhea, chronic lower back pain, acute gouty arthritis and ankylosing spondylitis. Merck noted no other coxib carries indications for the latter three indications. A late 2004 approval is predicted. While Arcoxia is three years behind Pfizer's follow-on COX-2 Bextra (valdecoxib), it could make it to market a year ahead of Novartis' Prexige, which was found "not approvable" Sept. 22 (1Pharmaceutical Approvals Monthly Oct. 1, 2003, In Brief)...
You may also be interested in...
Novartis COX-2 setback
Approval of Novartis' COX-2 inhibitor Prexige (lumiracoxib) could be delayed until 2005-2006 with the receipt of a Sept. 22 "not approvable" letter. FDA is requesting final data from the long-term TARGET study, additional data on the dose and dose interval in acute pain models, and an additional hip osteoarthritis study. TARGET results could be submitted third quarter 2004; an additional hip OA study would not be ready until the second half of 2005. The timeline could be accelerated if FDA accepts data from ongoing studies. Novartis will discuss requirements for individual trials with FDA "in the next two to four weeks." Global Pharma Development Head Joerg Reinhardt, PhD, assured investors Sept. 24 that FDA is "not addressing a specific liver enzyme elevation problem, it's an overall risk-benefit efficacy/safety assessment"...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.